RESUMO
ABSTRACT: Prostate-specific membrane antigen (PSMA) PET/CT is widely used in the evaluation of suspected metastasis for initial definitive therapy and suspected recurrence of prostate cancer. We outline a case report of a 62-year-old man with history of prostate cancer treated with surgery, salvage radiation, and hormonal therapy presenting with rising PSA levels. There was incidental detection of a PSMA-avid subcutaneous abdominal wall mass on PSMA PET/CT study, which was consistent with desmoid fibromatosis on an ultrasound-guided biopsy.
Assuntos
Parede Abdominal , Antígenos de Superfície , Glutamato Carboxipeptidase II , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Humanos , Masculino , Pessoa de Meia-Idade , Glutamato Carboxipeptidase II/metabolismo , Parede Abdominal/diagnóstico por imagem , Parede Abdominal/patologia , Antígenos de Superfície/metabolismo , Fibromatose Agressiva/diagnóstico por imagem , Neoplasias Abdominais/diagnóstico por imagem , Tomografia Computadorizada por Raios XRESUMO
ABSTRACT: COVID-19 vaccination has started in most countries, and postvaccination imaging is inevitable in the oncologic population. The immune response to the vaccination in the form of reactive lymphadenopathy has been well documented on 18F-FDG PET/CT. We present the imaging findings of 3 patients who have undergone non-FDG PET/CT imaging including 18F-fluorthanatrace, 68Ga-DOTATATE, and 18F-fluciclovine PET/CT. It is crucial to recognize the timing and laterality of immunization to avoid false-positive findings.
Assuntos
COVID-19 , Linfadenopatia , Vacinas contra COVID-19 , Fluordesoxiglucose F18 , Humanos , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Tomografia por Emissão de Pósitrons , Cintilografia , SARS-CoV-2 , VacinaçãoRESUMO
ABSTRACT: 18F-Fluciclovine PET/CT has become a common diagnostic imaging study used in the evaluation of biochemical recurrence in prostate cancer since its approval in 2016. We present a case report of an 82-year-old man with history of both prostate and bladder cancer who presented for a fluciclovine study due to rising PSA levels. There was incidental detection of focal penile activity, and a subsequent urethral biopsy performed showed urothelial carcinoma, which was also seen on a subsequent MRI study.
Assuntos
Ácidos Carboxílicos , Ciclobutanos , Achados Incidentais , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Neoplasias Urológicas/diagnóstico por imagem , Idoso de 80 Anos ou mais , Humanos , Imageamento por Ressonância Magnética , Masculino , Neoplasias da Próstata/diagnóstico por imagem , RecidivaRESUMO
Prostate cancer (PCa) is the most common noncutaneous malignancy in men and the second leading cause of cancer related death in the United States. Men with clinical suspicion of PCa undergo tissue sampling and based on features including the Gleason score, Prostate Specific antigen (PSA) levels and clinical tumor (T) stage, patients are risk stratified into 6 major groups based on National Comprehensive Cancer Network (NCCN) guidelines. This forms the basis for deciding imaging and management. Active surveillance is the preferred approach for less aggressive tumors. Surgery or radiation +/- androgen deprivation therapy continue to be the primary treatment options for localized disease. Imaging plays a critical role in the diagnosis, staging and management of PCa. Multiparametric magnetic resonance imaging (mpMRI) is currently the imaging modality of choice for locoregional staging. MRI, computed tomography and bone scan remain the preferred modalities for evaluation of nodal, soft tissue, and bone metastases, respectively. Advanced positron emission tomography imaging using novel radiotracers are being developed but are not yet integrated in the diagnostic guidelines for initial staging. In this review, we will discuss the imaging and treatment algorithms based on the NCCN risk groups, describe the utility of individual modalities, review Prosate Imaging and Reporting and Data System (PIRADS) version 2.1 for the reporting of mpMRI of the prostate.